BIOTE CORP -A (BTMD) Stock Fundamental Analysis
USA - NASDAQ:BTMD - US0906831039 - Common Stock
3.37 USD
+0.08 (+2.43%)
3.37 USD
0 (0%)
BTMD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. BTMD has an average financial health and profitability rating. BTMD scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year BTMD was profitable.
BTMD had a positive operating cash flow in the past year.
BTMD had positive earnings in 4 of the past 5 years.
BTMD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
BTMD's Return On Assets of 29.87% is amongst the best of the industry. BTMD outperforms 98.46% of its industry peers.
BTMD has a better Return On Invested Capital (51.55%) than 99.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.87% | ||
| ROE | N/A | ||
| ROIC | 51.55% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BTMD's Profit Margin of 15.73% is amongst the best of the industry. BTMD outperforms 89.74% of its industry peers.
BTMD's Profit Margin has declined in the last couple of years.
BTMD has a better Operating Margin (17.79%) than 86.67% of its industry peers.
BTMD's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 71.89%, BTMD is doing good in the industry, outperforming 80.00% of the companies in the same industry.
BTMD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.79% | ||
| PM (TTM) | 15.73% | ||
| GM | 71.89% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
The number of shares outstanding for BTMD has been reduced compared to 1 year ago.
Compared to 1 year ago, BTMD has a worse debt to assets ratio.
2.2 Solvency
BTMD has an Altman-Z score of 2.47. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.47, BTMD is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
The Debt to FCF ratio of BTMD is 4.35, which is a neutral value as it means it would take BTMD, 4.35 years of fcf income to pay off all of its debts.
BTMD has a better Debt to FCF ratio (4.35) than 85.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.35 | ||
| Altman-Z | 2.47 |
ROIC/WACC5.22
WACC9.87%
2.3 Liquidity
BTMD has a Current Ratio of 0.98. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
BTMD has a Current ratio of 0.98. This is amonst the worse of the industry: BTMD underperforms 82.56% of its industry peers.
A Quick Ratio of 0.74 indicates that BTMD may have some problems paying its short term obligations.
With a Quick ratio value of 0.74, BTMD is not doing good in the industry: 84.10% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 366.67% over the past year.
The earnings per share for BTMD have been decreasing by -48.53% on average. This is quite bad
The Revenue for BTMD has decreased by -14.94% in the past year. This is quite bad
Measured over the past years, BTMD shows a quite strong growth in Revenue. The Revenue has been growing by 12.38% on average per year.
EPS 1Y (TTM)366.67%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%220%
Revenue 1Y (TTM)-14.94%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-0.62%
3.2 Future
Based on estimates for the next years, BTMD will show a very strong growth in Earnings Per Share. The EPS will grow by 42.78% on average per year.
Based on estimates for the next years, BTMD will show a small growth in Revenue. The Revenue will grow by 6.82% on average per year.
EPS Next Y166.59%
EPS Next 2Y40.1%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 3.44, which indicates a rather cheap valuation of BTMD.
Compared to the rest of the industry, the Price/Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 97.44% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of BTMD to the average of the S&P500 Index (27.43), we can say BTMD is valued rather cheaply.
BTMD is valuated cheaply with a Price/Forward Earnings ratio of 7.80.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 91.79% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of BTMD to the average of the S&P500 Index (22.87), we can say BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.44 | ||
| Fwd PE | 7.8 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaper than 92.31% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BTMD is valued cheaper than 97.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.81 | ||
| EV/EBITDA | 7.61 |
4.3 Compensation for Growth
BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BTMD may justify a higher PE ratio.
BTMD's earnings are expected to grow with 24.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y40.1%
EPS Next 3Y24.88%
5. Dividend
5.1 Amount
BTMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.37
+0.08 (+2.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners66.02%
Inst Owner Change-1.76%
Ins Owners9.81%
Ins Owner Change8.21%
Market Cap166.61M
Analysts81.67
Price Target5.51 (63.5%)
Short Float %2.81%
Short Ratio5.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)318.36%
Min EPS beat(2)178.65%
Max EPS beat(2)458.07%
EPS beat(4)3
Avg EPS beat(4)223.56%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)86.5%
EPS beat(12)6
Avg EPS beat(12)-127.37%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)1.66%
Revenue beat(4)1
Avg Revenue beat(4)-2.07%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-2.3%
Revenue beat(12)4
Avg Revenue beat(12)-1.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.93%
PT rev (3m)-18.93%
EPS NQ rev (1m)-54.83%
EPS NQ rev (3m)-72.55%
EPS NY rev (1m)-5.74%
EPS NY rev (3m)-1.43%
Revenue NQ rev (1m)-8.94%
Revenue NQ rev (3m)-19.27%
Revenue NY rev (1m)-5.86%
Revenue NY rev (3m)-5.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.44 | ||
| Fwd PE | 7.8 | ||
| P/S | 0.84 | ||
| P/FCF | 4.81 | ||
| P/OCF | 4.02 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.61 |
EPS(TTM)0.98
EY29.08%
EPS(NY)0.43
Fwd EY12.81%
FCF(TTM)0.7
FCFY20.77%
OCF(TTM)0.84
OCFY24.89%
SpS4.03
BVpS-1.72
TBVpS-2.01
PEG (NY)0.02
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.87% | ||
| ROE | N/A | ||
| ROCE | 65.25% | ||
| ROIC | 51.55% | ||
| ROICexc | 80.7% | ||
| ROICexgc | 137.37% | ||
| OM | 17.79% | ||
| PM (TTM) | 15.73% | ||
| GM | 71.89% | ||
| FCFM | 17.39% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-32.05%
ROICexcg growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score6
Asset Turnover1.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.35 | ||
| Debt/EBITDA | 2.98 | ||
| Cap/Depr | 184.76% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 3.69 | ||
| Cash Conversion | 106.02% | ||
| Profit Quality | 110.56% | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | 2.47 |
F-Score6
WACC9.87%
ROIC/WACC5.22
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)366.67%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%220%
EPS Next Y166.59%
EPS Next 2Y40.1%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue 1Y (TTM)-14.94%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-0.62%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
EBIT growth 1Y-11.91%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year53.39%
EBIT Next 3Y25.44%
EBIT Next 5Y14.88%
FCF growth 1Y14.31%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y28.77%
OCF growth 3Y10.29%
OCF growth 5Y12.28%